ReviewCancer management and research2019

Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.

Reshma L Mahtani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.